Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Scognamiglio T. C Cell and Follicular Epithelial Cell Precursor Lesions of the Thyroid. Arch Pathol Lab Med. 2017;141(12):1646-1652.

Tyekucheva S, Bowden M, Bango C, Giunchi F, Huang Y, Zhou C, et al. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun. 2017;8(1):420.

Pizzi M, Inghirami G. Patient-derived tumor xenografts of lymphoproliferative disorders: are they surrogates for the human disease? Curr Opin Hematol. 2017;24(4):384-392.

Kossatz S, Carney B, Schweitzer M, Carlucci G, Miloushev VZ, Maachani UB, et al. Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. Cancer Res. 2017;77(8):2112-2123.

Wang SA, Hasserjian RP, Tam W, Tsai AG, Geyer JT, George TI, et al. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017;102(8):1352-1360.

Begum A, Ewachiw T, Jung C, Huang A, K Norberg J, Marchionni L, et al. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLoS One. 2017;12(7):e0180181.

Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. Am J Psychiatry. 2017;174(7):695-696.

Wolgast LR, Arslan AA, Wu X-, Beyda JN, Pengo V, Rand JH. Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody-positive patients with adverse clinical outcomes. J Thromb Haemost. 2017;15(7):1412-1421.

Wilkes DC, Sailer V, Xue H, Cheng H, Collins CC, Gleave M, et al. A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Cold Spring Harb Mol Case Stud. 2017;3(5).

Olsen SN, Wronski A, Castaño Z, Dake B, Malone C, De Raedt T, et al. Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. Cancer Discov. 2017;7(2):202-217.